News About: Pharm. Industry
KOSPI and KOSDAQ listed pharmas had more than 10% growths in sales
The KOSPI and KOSDAQ listed pharmaceutical companies’ average collective sales were increased by more than 10% in the 3rd quarter compared to the same quarter of the last year. On the other hand, their 3rd quarter’s s...
Prior notice to compete between Samsung and LG over ‘bio-pharma’ field
LG Group decided to jump into the biopharmaceutical business. With Samsung Group which started large investments in the field, thus, the biopharmaceutical field is, too, expected to become an arena for large companies...
Innovative pharmas spend 12% of sales into R&D
It was observed innovative pharmaceutical companies spent 12% of their sales into R&D on average, and Celltrion and Hanmi Pharm were the ones which spend the most.
According to the Yakup Shinmoon’s(www.yakup.com) ana...
Listed pharmas with increase in net profit
The KOSDAQ listed pharmaceutical companies’ collective net profit ratio against sales was 3 times higher than the one of listed pharmaceutical companies in the KOSPI market. Their average growth rate was 6 times highe...
KOSDAQ records 3 times higher than KOSPI in collective operating profits
The KOSDAQ listed pharmaceutical companies’ average collective operating profit rate this year was 3 times higher than the one of KOSPI listed pharmaceutical companies.
According to the Yakup Shinmoon’s(www.yakup.com...
Why Korean pharma industry lacks in acquiring new drug approvals?
It was criticized the pharmaceutical industry lacks in new drug development as only having one drug developed by Korean pharmaceutical companies this year.
While there were 5 new drugs developed last year, ‘Olita Tab...
Cashable assets owned by listed pharma are reaching for KRW 2 trillion
Cashable assets owned by listed pharmaceutical companies are reaching for KRW 2 trillion.
According to the Yakup Shinmoon’s(www.yakup.com) analysis result of 2016 3rd quarter reports turned in by KOSPI and KOSDAQ li...
Dong-A ST’s partnership with GSK ends on November
Dong-A ST made a notice on the 24th that the strategic partnership, which was made on May 2010 when they were Dong-A Pharm, to jointly sell the products of GlaxoSmithKline(GSK) with GSK will end on November 30, 2016. ...
‘Celltrion’ becomes top in spending R&D expenses
The KOSDAQ listed pharmaceutical companies’ average R&D expense/sales rate in the 3rd quarter exceeded 10%, and the one for KOSPI listed pharmaceutical companies did not reach 10%.
According to the Yakup Shinmoon’s(w...
Effect of Kim Young-Ran Law made pharmas cut entertainment expenses
It was observed entertainment expenses for listed pharmaceutical companies were increased by 7% compared to the last year. Particularly, the rate of entertainment expenses against sales by the first half was similar w...
